A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery
| Autor: | Ji-hua Han, Shan-shan Qin, Juan Pu, Weiguo Zhu, Fu-zhi Ji, Yan Zhang, Jin-xia Ding, Chang-Hua Yu, Jun-xia Sun, Xi-Lei Zhou, Tao Li, Ya-lin Ji, Guang-zhou Tao |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Brachytherapy Urology Uterine Cervical Neoplasms Docetaxel Adenocarcinoma Hysterectomy Young Adult Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radical surgery Survival rate Aged Neoplasm Staging Cervical cancer Chemotherapy business.industry General Medicine Chemoradiotherapy Middle Aged medicine.disease Prognosis Radiation therapy Survival Rate Carcinoma Squamous Cell Female Taxoids Radiotherapy Intensity-Modulated Cisplatin Neoplasm Recurrence Local business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of cancer research and clinical oncology. 139(4) |
| ISSN: | 1432-1335 |
| Popis: | This study explored whether docetaxel/cisplatin and radiotherapy (TP-R) increases overall survival (OS) and recurrence-free survival (RFS) compared to single-agent cisplatin and radiotherapy (C-R) in patients with high-risk early-stage cervical cancer post surgery.Patients with clinical stage IB and IIA carcinoma of the cervix, initially treated with radical hysterectomy and pelvic lymphadenectomy, and who had positive pelvic lymph nodes and/or positive margins and/or the diameter of the primary tumor ≥4 cm and/or depth of interstitial infiltration ≥1/2 and/or lymphovascular space invasion were eligible for this study. Patients were randomized to receive C-R or TP-R. Radiotherapy in both groups was external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy). Patients were given cisplatin (40 mg/m(2)) every week for five cycles (C-R group) or docetaxel (30 mg/m(2)) and cisplatin (30 mg/m(2)) every week for five cycles (TP-R group).Between 2003 and 2008, 320 patients were entered onto the study. Final analyses included 285 patients. One hundred and forty patients comprised the C-R group and 145 were in the TP-R group. The 5-year OS were 74.3 % in the C-R group and 82.8 % in the TP-R group. The hazard ratio (HR) for death was 0.65 in the TP-R group (95 % CI: 0.39-1.09, P = 0.098). The RFS were 69.3 % in the C-R group and 79.3 % in the TP-R group, and the HR for recurrence was 0.64 in the TP-R group (95 % CI: 0.40-1.03, P = 0.061). Recurrence rates were similar in both groups (27 in the C-R group and 18 in the TP-R group, P = 0.112). The seriousness of late side effects was similar in the two groups, with a higher rate of reversible hematological effects in the TP-R group.Compared with single-agent cisplatin and radiotherapy, docetaxel/cisplatin in combination with radiotherapy does not increase OS but has the trend of increasing RFS in patients with high-risk early-stage cervical cancer. However, docetaxel/cisplatin in combination with radiotherapy is associated with a higher incidence of side effects, this effect was reversible, and the incidence of late side effects was similar in the two treatment groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink